Cargando…

NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations

The aim of this paper is to review and up to date the prevalence of hepatitis C virus (HCV)-associated non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and their significance in both accelerating progression of HCV-related liver disease and development of HCV-associ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adinolfi, Luigi Elio, Rinaldi, Luca, Guerrera, Barbara, Restivo, Luciano, Marrone, Aldo, Giordano, Mauro, Zampino, Rosa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926337/ https://www.ncbi.nlm.nih.gov/pubmed/27231906 http://dx.doi.org/10.3390/ijms17060803

Ejemplares similares

Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH
por: Colognesi, Martina, et al.
Publicado: (2020)

HCV Extrahepatic Manifestations
por: Kuna, Lucija, et al.
Publicado: (2019)

Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics
por: Rinaldi, Luca, et al.
Publicado: (2020)

Extrahepatic Manifestations of Chronic HBV Infection and the Role of Antiviral Therapy
por: Mazzaro, Cesare, et al.
Publicado: (2022)

Natural History of NAFLD/NASH
por: Ekstedt, Mattias, et al.
Publicado: (2017)

The role of the microbiome in NAFLD and NASH
por: Kolodziejczyk, Aleksandra A, et al.
Publicado: (2018)

Noninvasive Diagnosis of NAFLD and NASH
por: Piazzolla, Valeria Annarita, et al.
Publicado: (2020)

Contribution of Metabolomics to the Understanding of NAFLD and NASH Syndromes: A Systematic Review
por: Piras, Cristina, et al.
Publicado: (2021)

Imaging biomarkers of NAFLD, NASH, and fibrosis
por: Ajmera, Veeral, et al.
Publicado: (2021)

Evolving Role for Pharmacotherapy in NAFLD/NASH
por: Attia, Suzanna L., et al.
Publicado: (2020)

Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct‐acting antivirals
por: Nevola, Riccardo, et al.
Publicado: (2020)

Current and future pharmacological therapies for NAFLD/NASH
por: Sumida, Yoshio, et al.
Publicado: (2017)

Lifestyle modification in NAFLD/NASH: Facts and figures
por: Hallsworth, Kate, et al.
Publicado: (2019)

Diet and exercise in NAFLD/NASH: Beyond the obvious
por: Semmler, Georg, et al.
Publicado: (2021)

Association of C-type lectin 18 levels with extrahepatic manifestations in chronic HCV infection
por: Liao, Tsai-Ling, et al.
Publicado: (2018)

The risk of HCV infection among health-care workers and its association with extrahepatic manifestations
por: Garozzo, Adriana, et al.
Publicado: (2017)

A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy
por: Mazzaro, Cesare, et al.
Publicado: (2021)

Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH
por: Wan, Xingyong, et al.
Publicado: (2016)

Current Options and Future Directions for NAFLD and NASH Treatment
por: Zhang, Chunye, et al.
Publicado: (2021)

Improved pathology reporting in NAFLD/NASH for clinical trials
por: Langford, Caitlin Rose, et al.
Publicado: (2022)

Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
por: Welch, Ryan D., et al.
Publicado: (2022)

Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
por: Finan, Brian, et al.
Publicado: (2020)

Deciphering the role of aberrant DNA methylation in NAFLD and NASH()
por: Vachher, Meenakshi, et al.
Publicado: (2022)

Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis
por: Rinaldi, Luca, et al.
Publicado: (2017)

Atypical Presentation of a Rare Parasitic Infection with Fasciola hepatica: A Multidisciplinary Case Report
por: Rinaldi, Luca, et al.
Publicado: (2020)

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD
por: Bazick, Jessica, et al.
Publicado: (2015)

Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models
por: Mahmoudi, Ali, et al.
Publicado: (2022)

Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions
por: Xu, Gao-Xin, et al.
Publicado: (2023)

A Systematic Review of NAFLD-Associated Extrahepatic Disorders in Youths
por: Pacifico, Lucia, et al.
Publicado: (2019)

Knowledge of liver fibrosis stage among adults with NAFLD/NASH improves adherence to lifestyle changes
por: Carrieri, Patrizia, et al.
Publicado: (2022)

Orbital Pseudotumor as an Extrahepatic Complication of Chronic HCV Infection
por: Huang, Owen, et al.
Publicado: (2018)

SAT-LB004 Therapeutic Potential of LPCN 1144 in NAFLD and NASH
por: Baker, Jonathan, et al.
Publicado: (2019)

Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH
por: Svegliati-Baroni, Gianluca, et al.
Publicado: (2020)

Modeling Diet-Induced NAFLD and NASH in Rats: A Comprehensive Review
por: Carreres, Lydie, et al.
Publicado: (2021)

Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC
por: Longo, Miriam, et al.
Publicado: (2021)

Non-Invasive Risk Stratification in NAFLD/NASH Patients for Screening EGD
por: Romano, John, et al.
Publicado: (2022)

Comprehensive Transcriptome Profiling of NAFLD- and NASH-Induced Skeletal Muscle Dysfunction
por: Guo, Mingwei, et al.
Publicado: (2022)

Dermatologic Extrahepatic Manifestations of Hepatitis C
por: Dedania, Bhavtosh, et al.
Publicado: (2015)

Extrahepatic Manifestations of Primary Biliary Cholangitis
por: Chalifoux, Sara L, et al.
Publicado: (2017)

Extrahepatic manifestations and HEV, the genotype matters
por: Horvatits, Thomas, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ugsa10fn15nnav7bmr2t3i9qbr